Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/VkPHT-DrLiA   A new bivalent Moderna CoVid vaccine that contains CoVid antigens from the original CoVid strain and from the feisty South African Beta B.1.351 variant more than doubles the titers of protective antibodies against Omicron for up to 6 months after the shot.  This from a pre-publication manuscript released by Moderna that does raise some questions about the power of this new booster to control our current cascade of new and more challenging Omicron sub-variants.   The CoVid mRNA boosters were administered to subjects fully vaccinated about 6 months previously with 2 shots of Moderna vaccine.  The boosts occurred in June through mid-July 2021 and subjects were monitored for antibody production at about one and six months.  Two dosages of the new vaccine were used, 50 ug and 100 ug, but complete results were only reported for the 50 ug dosage.  The antibody production triggered by this new vaccine was compared with that induced in the past by a boost of the original vacc